A White House deal with Eli Lilly & Co. and Novo Nordisk to lower the prices of their popular obesity medicines, Zepbound and ...

The deal involves Eli Lilly, which makes Zepbound and Mounjaro, and Novo Nordisk, the maker of Ozempic and Wegovy. The drugs, known as GLP-1 medications, now cost as much as $1350 a month. Under the ...

Oral GLP-1 weight loss pills could replace injections by March 2026 at $150 monthly, Medicare chief Dr. Mehmet Oz predicted in a FOX Business appearance.

Novo Nordisk NVO is a dominant player in the cardiometabolic space, which markets its blockbuster semaglutide-based (GLP-1) ...

Drugs like Wegovy and Ozempic have been in high demand after they were found to help in losing weight. But could a Trump ...

Novo Nordisk navigates competition and guidance challenges with strong profitability and upcoming oral Wegovy opportunities.

Weight loss drugs like Zepbound and Wegovy will become more accessible to millions of Americans after the Trump ...

Those weight loss drugs that have been so out of reach for many, may soon be affordable, even if you don't have insurance.

Donald Trump hailed his deal to slash the price of blockbuster weight loss drugs as a game changer. But major gaps in the ...

People taking GLP-1 meds could see costs drop in 2026, thanks to a new federal deal with Eli Lilly and Novo Nordisk, the ...

The deal announced on Thursday, covering Novo's Wegovy and Lilly's Zepbound, will reduce monthly prices for U.S. government ...

The U.S. Food and Drug Administration said on Thursday it has awarded six more companies, including Eli Lilly and Novo ...